Severe Combined Immunodeficiency (SCID) Diagnosis Market Size, Share, Industry, Forecast and outlook (2024-2031)

Severe Combined Immunodeficiency (SCID) Diagnosis Market By Test Type ( TREC,  Complete blood count (CBC),  Genetic Test,  Biochemical Test), By End-User ( Hospitals,  Ambulatory Surgical Centers,  Others), By Region (North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.

Severe Combined Immunodeficiency (SCID) Diagnosis Market Size

The Global Severe Combined Immunodeficiency (SCID) Diagnosis Market reached US$ 196.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 423.5 million by 2030. The global severe combined immunodeficiency (SCID) diagnosis market is expected to exhibit a CAGR of 10.4% during the forecast period (2023-2030).  The severe combined immunodeficiency (SCID) diagnosis market trends show rising incidence of disease type and product launches for diagnostics owing to the rising technologies and increasing research and development.

The severe combined immunodeficiency (SCID) diagnosis market involves tests and procedures that confirm the presence of disease and identify the correct tumor type, location, extent, and stage, which will help a physician give the appropriate treatment.

Furthermore, rising consumer demand for diagnostics due to the rising availability of disease and test types, an increase in the number of approved tests in the market, and an increase in research are driving up the severe combined immunodeficiency (SCID) diagnosis market size. The market is experiencing a growing demand for test types from North American areas as a result of the rising advancements in this field with significant competitors like ARCHIMED Life Science GmbH, Leadiant Biosciences, Inc., Labsystems Diagnostics Oy, and others actively operating in the market.

Severe Combined Immunodeficiency (SCID) Diagnosis Market Scope

For More Insights about the Market Request Free Sample

Severe Combined Immunodeficiency (SCID) Diagnosis Market Dynamics

Increased Awareness of Diagnostic Procedures Drives the Growth of the Severe Combined Immunodeficiency (SCID) Diagnosis Market

For the diagnosis of severe combined immunodeficiency (SCID), a thorough medical history including a physical examination of the child is typically required. To assist in confirming the diagnosis, blood tests such as a total red blood cell count along with others might be carried out. SCID can often be found in newborns before any symptoms show. In an increasing number of states, newborn screening is now mandated and includes testing for SCID. 

Since a lot of babies with SCID don't show any indications until they contract an infection, getting checked is very important. B- and T-lymphocyte levels in blood samples of patients thought to have SCID are analyzed by pathologists. The samples also reveal a decrease in the number of lymphocytes in addition to low or absent levels of antigen-fighting antibodies. 

Although exceedingly rare since neonates are not routinely tested for differential blood counts, early detection of SCID may preserve a child's life. Thus, from the above statements, the market is expected to drive in the forecast period.

Increasing Incidence of Severe Combined Immunodeficiency (SCID) Disorder Creates Lucrative Opportunities  for Manufacturers

Genetic changes that affect T cell activation are the cause of SCID. Depending on the SCID type, B and NK cells may change. These cells are essential for the immune system's defense against the bacteria, viruses, and fungi that cause infections. Affected neonates typically pass away in the first year of life without treatment by hematopoietic stem cell transplantation (HSCT). 

Early identification of infants who are at risk for SCID can speed up the transplantation process and improve post-transplant outcomes. The best probability of success is with transplants done within the initial three months of life. There are numerous variations of SCID. The most common type is brought on by a male-only X chromosome gene mutation.

The disease may exist in women, although both genders have a healthy X chromosome. Recessive forms of the disorder, which can affect both boys and girls, have increased in prevalence since the introduction of SCID screening. Other varieties of SCID are caused by a variety of genetic disorders as well as a deficiency in the enzyme adenosine deaminase.

Delayed and Improper Diagnosis will Hamper The Growth Of The Market. 

A serious infection may be the first indication that something is wrong and cause the baby's condition to quickly deteriorate, forcing a rapid admittance to the hospital and at times to an inpatient unit. Normal tests may indicate SCID, particularly if the blood lymphocyte count is low. 

An infant gets directed to a specialized immunology center as soon as the likelihood of SCID is identified. Additional testing will be necessary to verify the diagnosis and, in the future, to identify the type of SCID. Patients with SCID are more prone to severe and recurrent infections, and without immune-rebuilding therapy, they fail to survive childhood.   

Severe Combined Immunodeficiency (SCID) Diagnosis Market Segment Analysis

The global severe combined immunodeficiency (SCID) diagnosis market is segmented based on disease type, test type, end user and region.

Owing to High Incidence, the X-linked SCID Disease Type Segment Accounted for Approximately 58.2% of the Severe Combined Immunodeficiency (SCID) Diagnosis Market Share

A genetic immune system disorder called SCID (X-linked severe combination immunodeficiency) almost exclusively affects men. Boys with X-linked SCID are more likely to experience repeated and prolonged illnesses because they lack the necessary immune cells to defend against some viruses, bacteria, and fungi. SCID in its X-linked form is the most prevalent kind. The condition is believed to affect a minimum of one out of each 50,000 to 100,000 babies, while the exact incidence is unknown.

Retrospective multicenter studies in North America, as well as Europe, have found that between 40% and 50% of SCID diagnoses are X-SCID. Approximately 22% of newborns with traditional SCID are of the X-linked type, according to findings of a newborn screening (NBS) study that included three million births that occurred in NBS programs throughout the United States. 

This lower estimate was supported by research done by NBS in California, which discovered that among 2.5 million newborns screened, 29% of neonates identified as having SCID carried the X-related variation. Except in areas where there is a founder effect or a high frequency of consanguinity, X-SCID continues to be the most prevalent genotype. According to the aforementioned factors, this segment held the biggest market share during the forecast period.

Source: DataM Intelligence Analysis (2023)

Severe Combined Immunodeficiency (SCID) Diagnosis Market Geographical Share

North America Accounted for Approximately 43.5% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for severe combined immunodeficiency (SCID) diagnosis for diagnostics and various research purposes in healthcare, manufacturers in North America have chance of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for severe combined immunodeficiency (SCID) diagnosis. 

Increasing expenditure on healthcare and rising awareness among people, advancement of technologies for diagnosis and treatment, and increase in biopharmaceutical establishment across the region are also contributing to the growth of the severe combined immunodeficiency (SCID) diagnosis market share of this region. 

The primary healthcare organizations and businesses' joint research endeavors as well as new product development that continuously aims to enhance available diagnostic and treatment options are also expected to contribute to the rising demand. Individuals are becoming more aware of various advanced product types that are being studied for immunodeficiency diagnosis for providing better treatment, leading to the expansion of the market in this region. The above-mentioned factors further prove the dominance of North America on a global scale.

Source: DataM Intelligence Analysis (2023)

Severe Combined Immunodeficiency (SCID) Diagnosis Market Key Players

The major global players in the severe combined immunodeficiency (SCID) diagnosis market include ARCHIMED Life Science GmbH, Revvity (PerkinElmer), Labsystems Diagnostics Oy, Revcovi, LaCAR MDx, Leadiant Biosciences, Inc., Winfertility, GSK Plc, CSL Behring and Devyser Diagnostics among others. 

COVID-19 Impact on Severe Combined Immunodeficiency (SCID) Diagnosis Market

Russia Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global severe combined immunodeficiency (SCID) diagnosis market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global severe combined immunodeficiency (SCID) diagnosis market growth over the forecast period.

Key Developments

• On March 27, 2023, parents of kids with SCID began a challenging path distinguished by a range of emotional and educational needs, even after being identified through newborn screening. The path with SCID was plagued by ongoing, complex uncertainties. The findings highlight the value of assisting parents in coping with uncertainty and preparing them for the SCID journey.
• On April 16, 2023, officials from CSL Plasma and CSL Behring joined forces with Prof. Dr. Volker Wahn along with other officials to hold a news conference to discuss PI patients and the unique characteristics of blood plasma therapy. A person with an initial immunodeficiency is born with a defective or insufficient immune system, leaving them susceptible to life-threatening diseases. The diagnosis process for patients is complicated by over 450 different types of PI.  
• On February 25, 2023, the latest research conducted by researchers shows that maintaining lymphocyte counts and detoxification in patients with ADA-SCID is possible with PEGylated Recombinant Adenosine Deaminase. When compared to pegademase therapy in individuals with ADA-SCID, elapegademase is safe, effectively tolerated, achieves constant trough plasma ADA activity with weekly dose, is successful in maintaining metabolic detoxification, and is related to maintenance or increase in lymphocyte counts.

Why Purchase the Report?

• To visualize the global severe combined immunodeficiency (SCID) diagnosis market segmentation based on disease type, test type, end user and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of severe combined immunodeficiency (SCID) diagnosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global severe combined immunodeficiency (SCID) diagnosis market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies